Read This First
This page is not built on clinical evidence, because none exists for this compound. Cost and access are commercial and legal facts, not scientific findings. They come from the regulatory record, and for KPV that record changed in July 2026 in a way that is easy to overstate.
KPV has no list price, no prescription route, no insurance pathway and no manufacturer, because it is not approved anywhere, has never been given to a human being in a study, and is not on the list of substances pharmacies may compound.1 An advisory committee has recommended that it be added, for a topical cream. The FDA has not acted.
This page publishes no prices. What follows is what determines the money.
Why There Is No Price
What a Price Normally Represents
For an approved medicine, a price sits on top of a known quantity of a known substance, made to a validated standard, for a stated indication, with a documented effect. For KPV every element is missing, and the last is missing in the most complete way possible: there is no human measurement of any effect, by any route, for any condition.1 A price on KPV is a number attached to a vial whose contents have never been tested in a person.
Why Is It Cheap to Make and Not Cheap to Buy?
KPV is three ordinary amino acids. Of all the peptides in this library it is the simplest to synthesise, and its raw material cost is correspondingly low. The gap between that and what it sells for is the market's pricing of a story: a fragment of a hormone, an anti-inflammatory signal in mice, a gut-delivery mechanism with a name, and now a committee vote. None of those is a property of the vial.
Access
Is There a Legal Route?
Not in the United States. KPV is not approved, is not a component of an approved drug, and is not on the 503A bulks list. It sat in the FDA's Category 2 of nominated compounding substances from September 2023 and is now listed as nominated but withdrawn.2
There is no clinical trial to join. No study of KPV is registered anywhere.3
What Did the July 2026 Vote Do?
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend KPV for the bulks list for wound healing and inflammatory conditions, over the FDA's objection that the substance was not well characterised and had no human safety or effectiveness data.41
Three things follow for access. The vote is advisory and non-binding. The list can only be amended by rulemaking, which has not begun and which, if it follows the ordinary process, takes a year or more; the FDA could instead announce enforcement discretion faster, and has not. And the nomination was for a 0.1 percent topical cream and gel, so even a favourable decision would create a lawful route for that product and not for the injectable, oral and nasal products that dominate the market.1
Until the FDA acts, the legal position is unchanged. When it acts, if it does, the change will be narrower than the market expects.
Does Insurance Cover It?
No, and there is nothing to appeal. Payers reimburse approved products for approved indications. Even a compounded product on a bulks list is not an approved drug, and compounded preparations generally fall outside pharmacy benefit coverage.
Can HSA or FSA Funds Be Used?
Tax-advantaged health accounts cover qualified medical expenses, which generally requires a legitimate medical purpose and often a provider's documentation. A product that cannot lawfully be dispensed for human use sits poorly against that. The account holder carries the consequences of a disallowed expense; the question belongs with the plan administrator.
What the Money Buys
Where Does the Spread Between Sellers Come From?
| Cost component | Present in | What it buys |
|---|---|---|
| Consultation and clinician time | Clinics, telehealth | A history, an examination, a record, and someone accountable |
| Premises, staff and liability | Clinics | Overhead and recourse, not product |
| Bundling into a "gut stack" with BPC-157 | Clinics, vendors | A second compound and a schedule, priced together so neither is examined alone; no study has tested the combination |
| The July 2026 vote | All channels, in the copy | Nothing; it changed no one's legal position and concerned a product most sellers do not offer |
| Marketing and affiliate commission | All channels, often invisible | Nothing for the buyer |
| The compound itself | All channels | Three amino acids of unverified purity and sterility, at a cost small relative to the components above it. ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown |
None of the spread buys verified product quality, because no channel offers that. A higher price buys service and accountability where those exist. It does not buy a human data point, because none exists at any price.
Does the Route Change the Cost?
Yes, and in an unusual direction. Topical KPV is the form with a plausible safety argument, since the peptide barely penetrates skin, and the form the committee recommended; it is also the form least likely to do anything, for the same reason.1 Oral KPV is digested unless formulated to survive, which the research formulations exist to achieve and a plain capsule does not.5 Injectable KPV delivers the peptide systemically and carries the sterility and endotoxin questions the FDA found unanswered on public certificates.
A buyer choosing between them is choosing which unknown to pay for.
The Spending Decision
What Result Is Being Paid For?
The product copy promises reduced inflammation, gut repair, and healing. In mice, KPV reduced chemically induced colitis and skin inflammation.56 In humans, nothing has been measured. The FDA's search found no clinical studies and no human exposure data by any route.1
That is a purer position than most compounds in this library occupy. There is no failed trial to explain away and no small positive trial to overread. There is a mechanism, an animal signal, and a blank.
A person who feels better on KPV has generated the first human observation of the compound. It is one, it is uncontrolled, and it is theirs.
What Is the Risk Side of the Ledger?
Probably low, and unmeasured. The compound is a fragment of a hormone everyone makes, and three natural amino acids are an unlikely toxin. But the FDA found no nonclinical toxicity studies of any kind, and its stated concern was "the lack of human data on drug products containing KPV administered via any route of administration, including lack of information to assess immunogenic safety risks."1 For an injectable of unverified sterility, the risk that matters is not the peptide.
What Should Be Asked Before Paying?
Which human study measured the outcome you are promising? The honest answer is none.
Are you aware the July 2026 recommendation was for a topical cream and has not been adopted by the FDA, and on what legal basis are you supplying this?1
For an injectable, can I see sterility and endotoxin results for the batch I will receive?
What is the price of each component of the stack separately?
Does anyone here earn commission on product sales?
What Would Change This Page
The FDA's Decision, or a Trial
The FDA's action on the July 2026 recommendation is the one scheduled event. If it adds KPV to the bulks list, a topical product would become compoundable on prescription, out of pocket, from pharmacies that would first need to source characterised material. The ONPEPS July 2026 article covers the two routes and their timescales.
A human trial of any design would be the first and would change the evidence section of every page about this compound. None is registered.
A Note on Price Comparisons
Figures circulate comparing KPV favourably with prescription anti-inflammatories and biologics for inflammatory bowel disease. The comparison is between drugs with measured effect sizes in thousands of patients and a tripeptide with none in anyone. ONPEPS does not make it.
Related ONPEPS Coverage
KPV library entry: the animal data, the absent human data and the July 2026 vote
KPV sourcing and quality: a tripeptide with no reference product
FDA peptide news July 2026: the votes, the dissent and what happens next
Sources
US Food and Drug Administration. KPV-related bulk drug substances (KPV (free base) and KPV acetate): FDA presentation to the Pharmacy Compounding Advisory Committee, 23 July 2026. Docket FDA-2025-N-6895. fda.gov
US Food and Drug Administration. Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Entry for KPV. Content current as of 22 April 2026. fda.gov
ClinicalTrials.gov. Studies listing KPV peptide as an intervention. Registry search returning no studies; checked 16 September 2026. clinicaltrials.gov
ONPEPS. FDA peptide news July 2026: the only source you need. Records the 8 to 6 vote with one abstention on KPV. onpeps.com
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. Open access. pubmed.ncbi.nlm.nih.gov/18061177
Macaluso A, McCoy D, Ceriani G, Watanabe T, Biltz J, Catania A, Lipton JM. Antiinflammatory influences of alpha-MSH molecules: central neurogenic and peripheral actions. J Neurosci. 1994;14(4):2377-2382. Open access. pubmed.ncbi.nlm.nih.gov/8158274
Not Medical or Financial Advice
KPV is not approved for human use in any jurisdiction and has never been studied in a human being. Treatment decisions belong with a qualified healthcare provider. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what is known about what the money would be spent on.
Sources verified 16 September 2026. The FDA's action on the July 2026 recommendation would change the access section of this page. Re-verify before relying on anything here.